On April 4, 2023 -Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, reported that its Chief Business Officer, Neil Abdollahian, will present at the 22nd Annual Needham Healthcare Conference which will take place virtually (Press release, Boundless Bio, APR 4, 2023, View Source [SID1234629824]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, April 18, 2023
Time: 4:30 – 5:10 PM ET

On April 4, 2023 TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 19, 2023 at 12:00 pm ET / 6:00 pm CET (Press release, Transgene, APR 4, 2023, View Source [SID1234629823]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The KOL webinar will provide insights on TG4050 from expert medical oncologist Professor Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology) who will also discuss the unmet medical need and outlook on treatment landscape for patients suffering from head and neck cancers. Prof. Ottensmeier’s presentation will be followed by a Q&A session.

In addition, Transgene’s management team will provide a company update, highlighting new Phase I data presented at AACR (Free AACR Whitepaper) on April 18, 2023, confirming the high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation.

To register for the event, please click here.

Transgene will also present eight posters and have a booth (#310) at AACR (Free AACR Whitepaper) which is taking place in Orlando, Florida, on April 14-19, 2023.

On April 4, 2023 Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, reported the successful completion of a Series A extension financing, raising a further 31 million EUR, following the 51 million EUR Series A financing in April 2021 (Press release, ADCendo, APR 4, 2023, View Source [SID1234629822]). The financing was led by Pontifax Venture Capital, a leading healthcare-focused venture capital firm and existing investors Novo Holdings and Ysios Capital. Current investors RA Capital Management, HealthCap and Gilde Healthcare participated as well. As part of the investment, Ohad Hammer, partner at Pontifax Venture Capital, will join the Adcendo Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

uPARAP is a novel cancer target overexpressed on the cell surface of sarcoma and other mesenchymal cancers. The intriguing expression profile and internalizing properties of uPARAP make it a highly attractive ADC target. uPARAP ADC has shown potential to be effective across multiple sarcoma subtypes, an indication with a very high unmet medical need.

Adcendo intends to use the proceeds from the financing to initiate a broad clinical development program for uPARAP ADC in Sarcoma and is also planning to advance the development of its 2nd ADC pipeline asset with Development Candidate Nomination (DCN) planned in H1 2024.

Michael Pehl, Chief Executive Officer of Adcendo, said: "This financing underscores the confidence that our investors have in Adcendo’s capabilities and potential to develop innovative ADC cancer therapies in high unmet medical need cancers. We are pleased to welcome Ohad Hammer to the Adcendo Board of Directors, who brings a wealth of experience in supporting and advancing early-stage biotech companies. 2022 was a pivotal year for Adcendo with the expansion of our team, uPARAP ADC Development Candidate Nomination and the recent linker/payload license agreement with Duality Biologics. This financing will enable us to ensure a broad development program of our lead asset uPARAP and further advance our 2nd first-in-class ADC pipeline asset."

Ohad Hammer, Board Director of Adcendo and Partner at Pontifax Venture Capital, commented: "We are excited to support Adcendo’s efforts to bring new treatments to patients with cancer as we continue our focus on seeking exciting transformative technologies to treat substantial unmet medical need indications. Adcendo’s ADC capabilities offer significant potential and I look forward to closely working with the team to develop their pipeline assets and bring innovative therapies to patients in need."

On April 4, 2023 Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, reported that they have mutually agreed to terminate their collaboration and licensing agreement (Press release, Beactica, APR 4, 2023, View Source [SID1234629821]). The collaboration focused on research and development of novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The LSD1 programme includes BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. The current lead indication for BEA-17 is glioblastoma, an indication that falls outside the scope of Oscotec’s strategic priorities.

As part of the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, and gain ownership of all results from the collaboration. No obligations will remain between the companies.

BEA-17 was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM).

"We have valued the opportunity to collaborate with Beactica Therapeutics and congratulate them on FDA’s Orphan Drug Designation to BEA-17 for the treatment of glioblastoma," said Dr Taeyoung Yoon, CEO/CSO of Oscotec. "For portfolio reasons, we have now decided to focus on internal assets that are more closely aligned with our strategic objectives."

"We have appreciated the collaboration with Oscotec and are pleased by what we have achieved together. Retaining global rights to the LSD1 programme increases the potential in Beactica and is well aligned with the Company’s ambition to itself become a clinical-stage company," said Dr Per Källblad, CEO of Beactica Therapeutics.

On April 4, 2023 Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) reported it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), in pancreatic cancer (PDAC) patients, following presentation of these results at the AACR (Free AACR Whitepaper) Annual Meeting 2023 (AACR 2023) (Press release, Cantargia, APR 4, 2023, View Source [SID1234629820]). The R&D Day will be hosted by Cantargia management and Prof. Eric Van Cutsem, principal investigator in the CANFOUR trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantargia recently announced new results from the phase I/IIa clinical trial CANFOUR, evaluating nadunolimab in combination with chemotherapy for treatment of PDAC, to be presented at AACR (Free AACR Whitepaper) 2023 on April 17, 2023. A key finding is that patients with high tumor levels of IL1RAP, the target of nadunolimab, benefit most from the treatment.

During the R&D Day, Prof. Van Cutsem, Division Head of Digestive Oncology at University of Leuven and University Hospitals Gasthuisberg in Leuven, Belgium, and renowned expert in PDAC, will discuss the current treatment landscape in PDAC and the relevance of the new nadunolimab data. He will be joined by Dr. Dominique Tersago and Dr. David Liberg from Cantargia’s management team.

Event details and registration information

Date and time: April 24, 2023 2:00-3:30 PM CET (8:00-9:30 AM EST).
Venue: Redeye, Mäster Samuelsgatan 42, 10 tr, Stockholm
The event will be conducted in English and a simultaneous live webcast will be available for those unable to attend in person at the following link. The webcast will also be accessible on-demand, shortly after the event, at Cantargia’s website www.cantargia.com. A live question and answer session will follow the formal presentations. Participation in the event on-site requires registration at the following link.

Program

Welcome and introduction to Cantargia – Göran Forsberg, CEO
Nadunolimab mechanism of action – David Liberg, VP Research
Clinical results including new biomarker data of nadunolimab – Dominique Tersago, CMO
Pancreatic cancer and relevance of nadunolimab results – Prof. Eric Van Cutsem
Cantargia’s ongoing clinical trials – Dominique Tersago
Upcoming milestones and concluding remarks – Göran Forsberg
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, at 12.30 CET on 4 April 2023.